info@example.com

+1 66589 14556

Targeted Therapy for Kidney Cancer

Targeted Therapy for Kidney Cancer

📖 4 min read Written and medically reviewed by Dr. Alhad Naragude, MBBS, MS, DrNB Urology Last updated: September 6, 2026

Targeted therapy for kidney cancer uses medicines that block specific pathways cancer cells depend on, particularly signals involved in blood-vessel formation and tumour growth. In renal cell carcinoma, tyrosine kinase inhibitors (TKIs) that affect VEGF-related pathways are commonly used, often in combination with immunotherapy for metastatic disease. Targeted therapy is different from conventional chemotherapy and has its own side-effect pattern. The best drug or combination depends on cancer subtype, previous treatment, general health, blood pressure, kidney and liver function, and the treatment goal.

What are common targeted therapies?

Kidney-cancer treatment may include VEGF/VEGFR-directed TKIs such as axitinib, cabozantinib, lenvatinib, pazopanib or sunitinib, as well as other pathway-specific agents in particular settings. The sequence changes as new evidence emerges, so the drug name should be tied to the current treatment plan rather than chosen from an internet list.

How are targeted drugs used?

  • Combined with an immune checkpoint inhibitor as initial therapy for many metastatic patients
  • Used as a later-line treatment after prior immunotherapy or another TKI
  • Used alone when a combination is unsuitable
  • Selected according to tumour histology and molecular features in particular subtypes

Common side effects

  • High blood pressure
  • Diarrhoea
  • Fatigue
  • Reduced appetite and weight loss
  • Hand-foot skin reaction
  • Mouth soreness
  • Thyroid changes
  • Liver-test abnormalities
  • Protein in the urine or kidney effects
  • Bleeding or clotting complications in selected patients

Monitoring while on treatment

Blood pressure should be checked regularly. Blood counts, kidney function, liver tests, thyroid function and urine protein may be monitored depending on the drug. Dose interruption or reduction is a standard toxicity-management strategy and does not automatically mean treatment has “failed.”

Targeted therapy and surgery

Systemic therapy is not a substitute for surgery in most clearly resectable localised kidney cancers. In metastatic disease, however, the timing and value of nephrectomy or metastasis-directed treatment are individualised around systemic therapy response and overall disease burden.

What targeted therapy is targeting

Most established kidney-cancer targeted drugs inhibit pathways involved in tumour blood-vessel signalling, particularly VEGF receptors. They do not target one mutation in the same way some lung-cancer tablets do. This distinction helps explain why blood pressure, diarrhoea, hand-foot symptoms, thyroid function and protein in urine can become important during treatment.

Tablets can still require intensive monitoring

Because many targeted treatments are oral, patients sometimes assume they are mild. VEGF tyrosine-kinase inhibitors can cause hypertension, fatigue, diarrhoea, mucosal soreness, liver-test abnormalities and, rarely, serious cardiovascular or bleeding complications. Dose interruption or reduction is common clinical management and does not mean the treatment has failed.

Where targeted therapy fits now

For metastatic clear-cell RCC, targeted drugs are frequently combined with checkpoint immunotherapy or used in later lines after an immune-based combination. Cabozantinib, axitinib, lenvatinib and other agents have different evidence and toxicity profiles; sequence depends on what has already been used and how the cancer behaved.

Targeted therapy is usually managed, not simply endured

VEGF-targeted drugs are often continued for months, so blood pressure, diarrhoea, mouth soreness, hand-foot symptoms, thyroid function, liver tests and fatigue matter. Dose reduction or a short treatment break can preserve long-term treatment without meaning that therapy has “failed.” Bring a home blood-pressure record and a complete medication list because drug interactions and uncontrolled hypertension are practical reasons treatment may need adjustment.

When to seek earlier medical review

During targeted therapy, report uncontrolled blood pressure, severe diarrhoea, painful hand-foot skin changes, bleeding, chest pain, significant shortness of breath or inability to maintain fluids. Do not stop or restart the drug on your own unless the oncology team has given an emergency plan.

Emergency warning signs

  • Very high blood pressure with severe headache, chest pain or neurological symptoms
  • Severe diarrhoea/dehydration or uncontrolled vomiting
  • Significant bleeding, chest pain or rapidly worsening breathlessness

What to bring to your consultation

  • Pathology and staging scans
  • Current targeted drug and treatment timeline
  • Home blood-pressure readings
  • Recent kidney/liver/thyroid tests and medication list

Questions to ask your doctor

  • Which pathway does this targeted drug block?
  • What blood-pressure and urine-protein monitoring will I need?
  • What is the next option if toxicity forces a dose reduction or stop?

FAQs

Is targeted therapy the same as chemotherapy?

No. It targets specific growth and vascular pathways and has a different mechanism and side-effect profile from classic cytotoxic chemotherapy.

Can I take a TKI continuously?

Some are taken on continuous schedules and others on defined cycles. Follow the exact prescription; do not alter timing or dose yourself.

Why does blood pressure rise?

VEGF-pathway inhibition can affect normal blood-vessel regulation, so hypertension is a recognised class effect and should be actively monitored.

Can targeted therapy be combined with immunotherapy?

Yes. Several current first-line kidney-cancer regimens combine a TKI with a checkpoint inhibitor.

Related reading

References

Note: This information is for educational purposes only and is not a substitute for medical advice. Please consult your doctor for any symptoms.